Testing Two Prostate Biopsy Methods to Detect Prostate Cancer
Compares a new micro-ultrasound biopsy with MRI-targeted biopsy in men at risk of prostate cancer.
Plain-language title generated from the registry record
Registry title: Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer
Key facts
- Where
- Salzburg, AustriaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06579911, who can take part
Where in Austria
- Uniklinikum Salzburg, Department for Urology and AndrologySalzburg, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Salzburger Landeskliniken
- Trial code
- NCT06579911
- Record updated
- 9 June 2026
- Original description
**Study Goal:** The purpose of this clinical trial is to determine if combining high-frequency micro-ultrasound with multiparametric MRI biopsy and a systematic biopsy can better detect clinically significant prostate cancer compared to current standard methods. This study is aimed at men who may have prostate cancer.Read full original descriptionShow less
Combining High-frequency Micro-ultrasound Target Biopsy and Multiparametric MRI Target Biopsy - Does it Increase the Detection Rate of Clinically Significant Prostate Cancer? A Prospective, Interventional, Single Centre, Randomized Controlled Trial
**Study Goal:** The purpose of this clinical trial is to determine if combining high-frequency micro-ultrasound with multiparametric MRI biopsy and a systematic biopsy can better detect clinically significant prostate cancer compared to current standard methods. This study is aimed at men who may have prostate cancer.
**Main Questions the Study Aims to Answer:**
1. Does the combination of new biopsy methods detect more clinically significant prostate cancers than the current standard method? 2. Does the new method not increase the detection of less serious forms of cancer beyond what the standard method detects?
**Participation in the Study:**
Participants in this study will undergo the following procedures:
* A high-frequency micro-ultrasound examination of the prostate. * A multiparametric MRI-targeted biopsy of the prostate. * A systematic biopsy of the prostate.
**Comparison Group:** Researchers will compare the new combination method with the current standard method to see if the new approach is more effective.
**Participants will:**
* Undergo several exams and biopsies depending on the results of previous tests. * Attend regular follow-up appointments to monitor potential side effects and evaluate prostate health. * Record their experiences and any symptoms in a diary.
Inclusion: Men with suspected clinically significant prostate cancer, identified by the rise in PSA level, suspicious digital rectal examination or both and pathologic multiparametric MRI of the prostate (>= PI-RADS III).
Exclusion: Patients with histopathologic proven prostate cancer; Untreated bacterial infection of the prostate; PSA > 20 ng/ml; Finding in digital rectal examination >= cT2c; Untreated coagulopathy.